The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs

David Frisvold; Meeshanthini Dogan; Timur Dogan; Khullani Abdullahi; Tyler Koep; Robert Philibert

doi:10.1007/s12325-024-02860-7

Back

The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs

Journal article

Open access

Peer reviewed

The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs

David Frisvold, Meeshanthini Dogan, Timur Dogan, Khullani Abdullahi, Tyler Koep and Robert Philibert

Advances in therapy, Vol.41(6), pp.2367-2380

04/25/2024

DOI: 10.1007/s12325-024-02860-7

PMCID: PMC11133094

PMID: 38662186

Files and links (1)

url

https://doi.org/10.1007/s12325-024-02860-7View

Published (Version of record) Open Access

Abstract

The cost of secondary prevention of coronary heart disease (CHD) is continuing to increase, with a substantial portion of this acceleration being driven by the expense of confirmatory diagnostic testing. Conceivably, newly developed precision epigenetic technologies could drive down these costs. However, at the current time, their impact on overall expense for CHD care is poorly understood. We hypothesized that the use of a newly developed, highly sensitive, and specific epigenetic test, PrecisionCHD, could decrease the costs of secondary prevention. To test this hypothesis, we constructed a budget impact analysis using a cost calculation model that examined the effects of substituting PrecisionCHD for conventional CHD diagnostic tests on the expenses of the initial evaluation and first year of care of stable CHD using a 1-year time horizon with no discounting. The model projected that for a commercial insurer with one million members, full adoption of PrecisionCHD as the primary method of initial CHD assessment would save approximately $113.6 million dollars in the initial year. These analyses support the use of precision epigenetic methods as part of the initial diagnosis and care of stable CHD and can meaningfully reduce cost. Real-world pilots to test the reliability of these analyses are indicated.

Epigenetics

In vitro diagnostics

Budget impact analysis

Artificial intelligence

Coronary heart disease

Details

Title: Subtitle: The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs
Creators: David Frisvold - University of Iowa
Meeshanthini Dogan - Cardio Diagnostics Inc, Chicago, IL, 60654, USA
Timur Dogan - Cardio Diagnostics Inc, Chicago, IL, 60654, USA
Khullani Abdullahi - Cardio Diagnostics Inc, Chicago, IL, 60654, USA
Tyler Koep - Cardio Diagnostics Inc, Chicago, IL, 60654, USA
Robert Philibert - Department of Psychiatry, University of Iowa, Iowa City, IA, 52242, USA. rphilibert@cardiodiagnosticsinc.com
Resource Type: Journal article
Publication Details: Advances in therapy, Vol.41(6), pp.2367-2380
DOI: 10.1007/s12325-024-02860-7
PMID: 38662186
PMCID: PMC11133094
NLM abbreviation: Adv Ther
eISSN: 1865-8652
Language: English
Electronic publication date: 04/25/2024
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Psychiatry; Economics; Iowa Neuroscience Institute
Record Identifier: 9984618501502771

Metrics

6 Record Views